Travere Therapeutics Draws Institutional Interest from Armistice Capital, Driehaus, and Wellington
Fourth quarter 2024 revenue reached $73.5 million, driven by FILSPARI's momentum in kidney disease treatment, while the company maintained a robust $370.7 million cash position. The performance has attracted attention from both specialized healthcare investors and broader institutional managers. FILSPARI and Regulatory Momentum
FILSPARI received full FDA approval in the third quarter of 2024 as the only non-immunosuppressive treatment that significantly slows kidney function decline in IgAN. The regulatory achievement transformed the drug from an accelerated approval based on surrogate endpoints to full approval based on clinically meaningful outcomes.
It initially received accelerated approval on February 17, 2023, for reducing proteinuria in adults with primary IgAN, with commercial availability beginning the week of February 27, 2023. Converting to full approval within 18 months reflects both the strength of clinical data and the company's regulatory execution capabilities.
The FDA recently accepted for review Travere's supplemental New Drug Application requesting modification of liver monitoring for FILSPARI in IgAN, with a target action date of August 28, 2025. Reducing monitoring requirements could expand patient access and physician adoption, factors that institutional investors monitor closely when evaluating commercial potential. Pipeline Expansion
Beyond IgAN, Travere is developing sparsentan to treat focal segmental glomerulosclerosis (FSGS), another rare kidney disease that often leads to kidney failure. FSGS damages the tiny filters in the kidneys, causing protein to leak into urine. Following meetings with the FDA, the company plans to submit a supplemental New Drug Application for FSGS treatment around the end of the first quarter of 2025, using data from two major clinical studies called DUPLEX and DUET.
If approved, sparsentan would become the first FDA-approved medicine specifically for FSGS patients, giving Travere a significant competitive advantage in treating this rare condition.
The company is also developing a drug called pegtibatinase for homocystinuria, a genetic disorder where the body cannot properly break down certain amino acids. This buildup can damage blood vessels and cause developmental delays.
International expansion could provide another growth avenue. Travere's partner Renalys Pharma expects results from its Phase 3 clinical trial of sparsentan for IgAN treatment in Japan during the second half of 2025. This partnership allows Travere to enter the Japanese market without direct investment while receiving milestone payments and future royalties if the treatment succeeds. Institutional Investment
Travere Therapeutics has 447 institutional owners holding a total of 117,537,916 shares, with the largest shareholders including Armistice Capital, BlackRock Inc., Janus Henderson Group, Vanguard Group Inc., and Driehaus Capital Management. The institutional ownership structure spans both passive index funds and active specialty investors.
Armistice Capital owns approximately 8.9 million shares, accounting for 2.38% of the hedge fund's portfolio. Other institutional participants include Wellington Management Group, which acquired a new stake during the fourth quarter, purchasing 33,493 shares valued at approximately $583,000. Emerald Advisers LLC raised its stake by 8.4% during the fourth quarter to 2,125,744 shares worth $37.03 million. Several major institutional investors expanded their Travere positions during the fourth quarter. Rock Springs Capital Management added 289,173 shares, bringing its total to nearly 5 million shares valued at $86.6 million. Renaissance Technologies increased its stake by 28.5% to 2.4 million shares worth $42 million.
Driehaus Capital Management made the largest percentage increase, adding over 1.9 million shares for a 608% jump. The firm now holds 2.2 million shares valued at $38.6 million. Jacobs Levy Equity Management grew its position by 37% to 2.2 million shares worth $37.9 million, while Emerald Advisers added 165,085 shares to reach 2.1 million shares valued at $37 million.
The combination of new entrants and existing shareholders increasing positions is a sign of continuing investor interest amid the stock's strong performance over the past year. Financial Position and Development Goals
Travere ended 2024 with approximately $371 million in cash, cash equivalents, and marketable securities. The financial position supports ongoing commercial activities and clinical development through multiple regulatory catalysts without requiring additional equity financing.
As of June 2025, Travere's market capitalization stood at approximately $1.27 billion. Meanwhile, the rare disease therapeutic market presents unique investment characteristics that attract institutional capital.
Institutional investors evaluate rare disease companies based on regulatory expertise, commercial execution capabilities, and pipeline diversification. Travere's progression from accelerated to full approval demonstrates regulatory competence, while consistent patient start form growth is a sign of commercial execution. The company's advancement of multiple indications for sparsentan and development of pegtibatinase provide portfolio diversification within the rare disease focus.
Investment from hedge funds such as Armistice Capital, Driehaus Capital Management, and Wellington Management reflects institutional positions on Travere's ability to execute on its rare disease focus. The combination of commercial revenue, regulatory momentum, and pipeline expansion opportunities continues to attract institutional capital to the company's equity.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 minutes ago
- Yahoo
From AI To Emerging Markets: How 6 Pros Would Allocate $10K In Today's Market
Amid record-high markets, six Wall Street strategists shared where they would deploy $10,000 right now, identifying areas ranging from artificial intelligence to emerging markets, according to Business Insider. Experts say there's still opportunity across various asset classes, including U.S. and global equities, small-cap stocks, and dividend-paying stocks. JPMorgan Backs International Stocks Over U.S. J.P. Morgan Asset Management Chief Market Strategist for the Americas Gabriela Santos said that she would allocate $7,000 to developed-market ex-U.S. equities and $3,000 to emerging markets, pointing out that U.S. stocks now trade at roughly a 35% premium to international peers—much higher than their historical 15% premium. Don't Miss: Accredited Investors: Grab Pre-IPO Shares of the AI Company Powering Hasbro, Sephora & MGM— 'Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. You can "After 15 years of disappointment, it's really been all about international equities this year — huge outperformance, and something we see as just the beginning," Santos told Business Insider. She added that a weaker U.S. dollar and growing investor interest in global markets support this shift. Santos cited the Vanguard FTSE Developed Markets ETF (NYSE:VEA) and iShares MSCI Emerging Markets ETF (NYSE:EEM), which were up 19.7% and 18.6%, respectively, as of last week. Stifel's Bannister Favors Diversified Equity Exposure With tech stocks dominating market headlines, Stifel Financial Corp (NYSE:SF, SFB)) Chief Equity Strategist Barry Bannister is steering in a different direction. He recommends spreading a $10,000 investment equally across small-cap, international, and value stocks to offset tech-sector concentration, Business Insider reported. 'Right now, the market's obsessively focused on tech. But it's hard to run an economy on seven stocks,' Bannister said. He highlighted the concentration risk in the tech sector and pointed to the Vanguard Value ETF (NYSE:VTV), iShares Russell 2000 ETF (NYSE:IWM), and iShares MSCI ACWI ex U.S. ETF (NASDAQ:ACWX) as preferred picks for diversification—and said he's recently adopted the approach himself using fresh capital received in May. Trending: $100k+ in investable assets? – no cost, no obligation. Equal Weight for Better Balance, Says Haverford Trust Haverford Trust Chief Investment Office Hank Smith recommended a two-part allocation: 50% to 60% in an equal-weighted S&P 500 ETF such as the Invesco S&P 500 Equal Weight ETF (NYSE:RSP) and 40% to 50% in a cap-weighted index such as the Nasdaq 100. Smith said equal weighting helps reduce overexposure to the top tech names, while the Nasdaq allocation ensures continued participation in any tech-driven rally. "Now you get all your top tech holdings that are driving this market," Smith told Business Insider. He said the approach works best with a minimum investment horizon of five years. Piper Sandler Emphasizes U.S. Large-Cap Leaders With elevated interest rates and a split in corporate earnings performance, investors may benefit more from selective stock-picking than from index investing, Piper Sandler (NYSE:PIPR) Chief Investment Officer Michael Kantrowitz told Business Insider. He said he expects U.S. large-cap leaders to continue outperforming and advised avoiding passive sector ETFs, which can misrepresent actual stock performance due to their weighting structures. "The earnings backdrop is going to be very bifurcated, and interest rates are going to remain elevated," Kantrowitz told the outlet. Companies currently screening well in Piper Sandler's models include Nvidia Corp. (NASDAQ:NVDA), Microsoft Corp. (NASDAQ:MSFT), Alphabet Inc. (NASDAQ:GOOG, GOOGL)), Meta Platforms Inc. (NASDAQ:META), Oracle Corp. (NYSE:ORCL), Costco Wholesale Corp. (NASDAQ:COST), Johnson & Johnson (NYSE:JNJ), and Home Depot Inc. (NYSE:HD).BlackRock Strategist Looks Beyond Just Tech Investors shouldn't abandon Big Tech — but diversification is key, according to BlackRock Inc. (NYSE:BLK) Global Chief Investment Officer of Fundamental Equities Tony DeSpirito, who manages several value-focused funds. 'I'm not negative on the Mag Seven,' he told Business Insider. 'Many of them have really good growth and really good free cash flow. That's an incredibly powerful combination, and so they earn the multiples that they're trading at.' DeSpirito recommends splitting a portfolio across large-cap growth, dividend stocks, and value plays to hedge against volatility. He flagged dividend names for their downside resilience and steady income, and called healthcare — especially medical device makers — a 'quality value' area that's been largely overlooked. The S&P 500 healthcare sector is down about 2% year-to-date. Still, he warned that some large pharmaceutical companies could be value traps, with earnings too dependent on soon-to-expire patents. Janus Henderson Sees Growth in Tech, Europe, and Mid-Caps Janus Henderson Group plc (NYSE:JHG) U.S. Head of Portfolio Construction and Strategy Lara Castleton recommended a diversified portfolio approach for investors with longer time horizons and higher risk tolerance. "We see strong potential in U.S. mid-caps and international equities," Castleton told Business Insider, recommending a three-part portfolio: 60% in large-cap U.S. equities with a tech tilt — via funds like the Invesco QQQ Trust (NASDAQ:QQQ) or Technology Select Sector SPDR Fund (NYSE:XLK) — along with 20% in ex-U.S. stocks, and 20% in U.S. mid-caps. She said international names, especially in Europe, are showing improved fundamentals, while U.S. mid-caps are benefiting from reshoring trends and offer greater upside than their larger peers. Read Next: Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die." Image: Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? APPLE (AAPL): Free Stock Analysis Report TESLA (TSLA): Free Stock Analysis Report This article From AI To Emerging Markets: How 6 Pros Would Allocate $10K In Today's Market originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved.
Yahoo
2 minutes ago
- Yahoo
The president fired the commissioner of the Bureau of Labor Statistics on Friday after the agency published a negative jobs report.
Former Treasury Secretary Larry Summers had choice words for President Donald Trump after he fired his stats boss over an abysmal jobs report. Trump fired Erika McEntarfer, the commissioner of the Bureau of Labor Statistics (BLS), on Friday after the agency released its July jobs report showing that the economy added a mere 73,000 jobs—far below the White House forecast of 109,000 jobs. BLS also revised its job numbers down for May and June by 258,000. Trump accused McEntarfer of having 'RIGGED' those numbers 'to make the Republicans, and ME, look bad.'
Yahoo
2 minutes ago
- Yahoo
Lando Norris ready to go all the way in championship battle with Oscar Piastri
Lando Norris believes his championship battle with Oscar Piastri will go to the wire following his victory at Sunday's Hungarian Grand Prix. Norris started third and dropped to fifth after a poor first corner at the Hungaroring before he rolled the strategy dice – stopping one less time than his rivals – to take the lead and then held off Piastri's late charge in a brilliant finale. Piastri came within centimetres of colliding with Norris on the penultimate lap when he momentarily lost control of his McLaren as he attempted a banzai move for the win. But Norris survived and held his nerve to keep the fast-charging Australian at bay to land his fifth win of the season – his third in his last four appearances – taking the chequered flag just six tenths clear and reducing the championship deficit to nine points with 10 rounds remaining. Max Verstappen, who finished ninth on Sunday, remains in third in the standings but 97 points off the championship pace. 'I'm dead,' said Norris. 'In the final stint Oscar was catching and I was pushing flat out. My voice has gone a little bit. 'It has been a tough battle so far with Oscar and it is going to continue to be tough. The margins between us are pretty small. There are things I can do better and improve on, and I am sure he will probably say the same thing. So, it is going to be a good and tough fight, probably until the end. 'Even though the results have looked great, I'm not making my life very easy at the minute. If I can work on those things, then I'll be in a better place.' Norris' win in the concluding round before the summer break reignites his bid to land a maiden world crown. But the Bristolian can count himself somewhat fortunate to be standing on the top step of the podium. At the start, Norris got away well from his marks, but an attempt to pass Piastri on the inside of the opening corner backfired. Norris did not commit to the overtake and that left him in no-man's land, allowing George Russell and then Aston Martin's Fernando Alonso to breeze through. On lap three, Norris fought his way clear of Alonso but was then tucked up behind Russell and making little progress. Piastri and Charles Leclerc, who controlled the first stint of the race from pole position, stopped for new tyres on laps 18 and 19 respectively. Russell also peeled into the pits on lap 19 promoting Norris to the front. McLaren were now considering a one-stop strategy. Norris' race engineer, Will Joseph, was on the radio: 'Lando, 40 laps on the hard tyre, you up for it?' Norris replied: 'Yeah, why not?' On lap 31 of 70, the Englishman came in for his sole change of tyres before lighting up the timesheets with the fastest laps of the race so far. In his haste to catch up, Norris then dropped two wheels through the gravel on the exit of the chicane, which irked Joseph. 'Lando, just keep the focus, we don't want these mistakes,' he said. Leclerc, Piastri and Russell were all forced to stop again. When it all shuffled out, Norris led Leclerc by seven seconds, with Piastri five seconds further back. But Piastri was on the move, swatting Leclerc aside on lap 51 and then set about reducing Norris' nine-second advantage. With five laps to go, Piastri was just a second behind his team-mate, and on the penultimate lap, the Australian went for glory at the first bend. However, Norris retained his composure and remained ahead to land what could be a pivotal win in his championship charge. Russell took the final place on the podium with Leclerc a disappointed fourth. The next race takes place in the Netherlands on August 31.
